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A 30-year-old woman was admitted to the University of Minnesota
Hospital to receive a second cadaveric renal transplant. Eighteen years
earlier, she had received her first cadavenc renal transplant for renal
failure due to chronic glomerulonephritis. She had been dialyzed for 4
months, during which time she underwent splenectomy and bilateral
nephrectomy. Tissue from the latter procedure demonstrated end-stage
renal disease consistent with chronic glomerulonephritis. She was
treated with azathioprine, 100 mg/day, and prednisone, 20 mg/day, as a
maintenance regimen initially; within one year, the prednisone dose
was reduced to 10mg daily. The patient's first renal aflograft functioned
well for several years; the serum creatinine concentration ranged
between 0.9 mg/dl and 1.1 mg/dl. Eleven years ago, the serum creati-
nine concentration rose to 2.9 mg/dl over 2 months; a graft biopsy
demonstrated acute tubulointerstitial rejection. The patient admitted to
noncompliance with her immunosuppressive regimen over several
weeks. The prednisone dosage was increased to 100 mg/day and then
tapered over the succeeding one month to 15 mg/day; the serum
creatinine concentration stabilized at 1.6 mg/dl.
Because of a rise in the serum creatinine concentration to 2.0 mg/dl,
a graft biopsy was repeated 5 years ago. The biopsy specimen demon-
strated chronic tubulointerstitial rejection and focal scarring with
changes of chronic vascular rejection. The immunosuppressive regimen
was continued, but propranolol, 20 mg twice daily, was begun because
of hypertension. Subsequently, the dose of propranolol was increased
to 40 mg twice daily; her blood pressure was controlled at approxi-
mately 135/85 mm -Hg. Because of a subsequent rise in the serum
creatinine concentration to 2.5 mg/dl 3 years prior to admission, the
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patient underwent a third renal biopsy of the graft, which demonstrated
severe chronic tubulointerstitial and vascular rejection. Over the suc-
ceeding 6 months, the serum creatinine rose to 3.9 mg/dl and her blood
pressure rose to 180/110 mm Hg. Urinalysis demonstrated 100 mg/dl of
protein on semi-quantitative testing. Furosemide, 20 mg/day, was
added to the antihypertensive regimen; her blood pressure promptly
responded and again was controlled in the range of 130/85 mm Hg. The
serum creatinine concentration gradually rose to a high of 4.9 mg/dl
over the succeeding 2 years. She developed progressive fatigue and
mild anorexia and was readmitted for renal transplantation.
The medical history also included carcinoma of the cervix, found on
routine gynecologic examination approximately 3 years prior to admis-
sion for the second renal transplant. She underwent total abdominal
hysterectomy; no evidence of nodal spread was found at operation.
On physical examination, the patient was an alert, cooperative young
woman in no distress. Her blood pressure was 150/100 mm Hg; pulse,
63 beats/mm and regular; and she was afebrile. Abdominal examination
revealed a soft abdomen with scars from previous surgery and a
nontender, palpable transplanted kidney in her right lower quadrant. A
hard cord, consistent with a clotted arteriovenous fistula, was palpable
in her left arm. She had no peripheral edema, and the remainder of the
physical examination was unremarkable.
Laboratory studies revealed a hemoglobin of 9.7 g/dl and a white
blood cell count of 8200/mm3. Urinalysis disclosed: specific gravity,
1.015; pH, 6.5; small amounts of blood; protein, 100 mg/dl; and the
sediment was unremarkable. The serum sodium was 141; potassium,
3.9; chloride, 102; and bicarbonate, 26 mmol/liter respectively; blood
glucose was 88; blood urea nitrogen, 72; serum creatinine, 4.4; calcium,
8.9; and phosphorus, 5.1 mg/dl, respectively; the serum albumin was
4.2 g/dl.
The patient underwent an en bloc transplantation of two kidneys from
a 2-year-old donor. The serum creatinine concentration descended
steadily; on discharge 11 days after transplantation it was 0.5 mg/dl. At
discharge the patient was taking cyclosporine, 200 mg twice daily;
azathioprine, 125 mg/day; and prednisone, 75 mg/day, which was
tapered to 17.5 mg/day over the succeeding 5 months. Her blood
pressure fell spontaneously to 110/70 mm Hg.
Discussion
DR. THOMAS H. HOSTETTER (Director, Division of Renal
Diseases and Hypertension, and Professor of Medicine, Uni-
versity of Minnesota Medical School, Minneapolis, Minneso-
ta): The term "chronic rejection" is often applied, in the
absence of other processes, to the slow decay in function (GFR)
of renal allografts in the months and years following a success-
ful initial engraftment. The term connotes a conceptual relation
to acute and hyperacute rejections for which relatively detailed
mechanisms are understood at molecular and cellular levels and
increasingly effective therapies have been developed. In the
case of chronic rejection, however, the mechanisms are largely
unknown, and no clearly effective therapy is available [1—5].
Hence the word "rejection" has been viewed by some as a
possible misnomer, and the more generic terms "chronic al-
lograft injury" or "chronic allograft dysfunction" are used
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synonymously. Furthermore, the basis for the diagnosis of this
process in the context of a slow decay in renal function has
varied from the clinical exclusion of other events (for example,
recurrent disease, renal artery stenosis, late acute rejection,
cyclosporine toxicity) to a stricter, biopsy-based definition
demanding specific findings, such as characteristic mural thick-
ening and occlusion of renal arteries, ischemic glomeruli, gb-
meruli with the nonspecific subendothelial deposits of trans-
plant glomerulopathy, interstitial infiltration with macrophages
and various lymphocyte subsets, and interstitial fibrosis. For
the purposes of this discussion, the terms chronic rejection and
chronic allograft injury are used interchangeably and confound-
ing processes such as recurrent disease are implicitly excluded.
To some extent, the haziness of diagnostic criteria and the
need for exclusion of other entities have hampered estimation
of the magnitude of this problem. That is, the exact number of
patients who re-develop end-stage renal disease (ESRD) due to
chronic rejection is uncertain. Studies from various centers,
including the University of Minnesota, suggest that if one
excludes patients dying with a functioning graft, from 50% to as
many as 80% of patients who return to dialysis do so because of
chronic rejection [6, 7]. On the other hand, if one includes
recipients dying with a functioning graft, approximately 25% of
graft failures are due to chronic rejection [1—4, 6].
One can reasonably estimate the quantitative contribution of
chronic rejection to the incidence of end-stage renal disease.
Let us assume that approximately 25% of graft failure is due to
this process (for this purpose, including death with a function-
ing graft, as a cause of overall graft failure). We include
mortality in order to apply the following estimate of the total
annual transplantation rate. We will further estimate an annual
average of 6000 renal transplants in the United States for the
last two decades (8000 to 10,000 have been performed annually
for the last 7 years). In a simple steady-state situation, then,
approximately 1500 patients would re-develop end-stage dis-
ease per year due to chronic rejection, with manyfold this
number in various stages of progression to ESRD [8, 9]. Given
the current published incidences of causes of treated ESRD in
the United States, this incidence would place chronic rejection
as one of the top categories of renal failure, exceeded only by
diabetes, hypertension, and glomerulonephritis [8]. It would
rank above any specific reported cause of glomerulonephritis.
Although these estimates are imprecise, they are reasonably
conservative estimates of the magnitude of the problem; as
assessed by histologic criteria, the prevalence of chronic rejec-
tion has been reported as high as two-thirds of cadaver trans-
plants that still function adequately at 2 years [31. Furthermore,
as treatments for infection and acute rejection continue to
improve, as do adjuvant maneuvers (such as prophylactic
coronary artery repair) that prevent untimely death, the fraction
of patients developing chronic rejection is likely to increase. At
the higher, current annual rates of transplantation, the absolute
numbers will of course escalate unless effective therapies are
developed.
The clinical manifestations of chronic rejection conform to
those of many chronic progressive renal diseases. Most impor-
tant, the filtration rate declines over months to years. We
assessed the rates of progression in patients with histologic
evidence of chronic rejection by applying the Cockcroft-Gault
formula to their serum creatinine levels [10]. The rate of decline
was generally within the range of that for other progressive
renal diseases, that is, approximately 0.5 mI/mm/month.
Considerable variability exists in the rate of progression
among patients, however [111. The rate of decay tended to
accelerate in most patients, although some investigators have
described attenuation of the rate of decline in a substantial
minority of patients with failing grafts [10, 11]. The risk of
developing chronic rejection increases directly with the dura-
tion of time following transplantation. In patients with a chronic
fall in GFR, the time to frank failure averages 3 to 4 years [11].
Even patients with grafts of many years duration, including
those with reasonably well functioning kidneys, almost always
have some biopsy evidence of chronic rejection, albeit mild
[12].
Proteinuria, a common accompaniment of chronic allograft
injury, usually is within the range of 1 to 2 glday. However,
nephrotic-range proteinuria can occur, most often in associa-
tion with chronic transplant glomerulopathy [13]. Arterial hy-
pertension is frequent in patients with chronic rejection: ap-
proximately 90% demonstrate hypertension and/or require
antihypertensive therapy, whereas only 50% or so of all renal
transplant patients are hypertensive [10, 14]. Arterial hyperten-
sion and proteinuria each confer added risk in chronic progres-
sive renal diseases in general and seem to do so in chronic
rejection as well. Employing an index comprising the number of
antihypertensive medications and the level of blood pressure,
Kasiske and colleagues demonstrated that the degree of histo-
logic damage of grafts with chronic rejection correlated with
this index [15]. In examining a cohort with histologic evidence
of chronic rejection, we showed that the rate of decline in renal
function, as estimated by serum creatinine, also correlated with
the level of diastolic blood pressure (Fig. 1) [10]. That is, the
patients with higher blood pressures had greater rates of decline
in renal function than did patients with lower arterial pressures.
This result is in overall agreement with the findings of Cheigh et
al that hypertension is associated with a greater rate of graft loss
[16]. Hence, the blood pressure is a correlate not only of the
degree of histologic damage but also of the tendency to declin-
ing function and its pace. Although proteinuria is usually
modest in chronic rejection, it too is a risk factor, as it is in most
other chronic renal diseases [13, 15, 17]. Although early in the
initial period following transplantation (up to 3 months), pro-
teinuria might not be predictive of late progression, but by one
year its prognostic weight is evident [11]. From a different
perspective, transplant recipients with declining creatinine
clearance tended to have a higher prevalence of proteinuria
(greater than I g/24 hr) [11]. Of even greater import was the
association of even 1 g/day of proteinuria with the degree of
histologic evidence of chronic rejection, especially vascular
thickening, interstitial fibrosis, glomerular basement membrane
reduplication, and a composite index of chronic rejection [151.
Finally, the observation that more than three-quarters of pa-
tients with greater than 2 g/day of proteinuria lost their grafts,
the majority within a year of developing this degree of protein-
uria, strongly supports the view that late proteinuria portends a
poor outcome [13].
Several additional clinical features are associated with the
appearance of chronic rejection (see Table 1). The number of
prior acute rejection episodes is greater in patients with chronic
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Fig. 1. Comparison of slopes of inverse serum creatinine over time
(vertical axis) with level of diastolic blood pressure (DBP) (horizontal
axis) greater than or less than 90 mm Hg in patients with biopsy-proven
chronic rejection. The slopes were analyzed for linearity and break-
points sought with resolution of the slope into two linear components.
Both before (A) and after (B) the breakpoint, more negative slopes
(more rapid decay) were associated with higher DBP (* P < 0.05).
(From Ref. 10.)
rejection than in those free of this complication [18]. Surpris-
ingly, the degree of HLA mismatch, however, has not consis-
tently been an important determinant of the appearance of
chronic rejection [1, 2, 15, 18]. The HLA matching of cadaveric
donor with recipient does, however, enhance both short- and
long-term survival of cadaveric grafts [19]. Although not
proven, it seems likely that mitigation of the rate of chronic
cadaveric graft loss by matching is related to diminution in
chronic rejection. In this regard, the reports of a lack of
association of matching with this process may have included
too few cases and/or failed to evaluate the degree or tempo of
the process, both of which may be adversely influenced by
histoincompatibility. That histocompatibility influences this
process, however indirectly, is also suggested by the shorter
hall-life of cadaver grafts compared with living-related organs
[1, 2, 19]. But when we analyzed the rate of progression in
patients with biopsy-proved chronic rejection, factors such as
gender, blood group (ABO), rejection episodes, HLA matching,
or even type of donor were not clearly linked to the rate of
decline in function [10]. Better HLA matches and fewer prior
acute rejection episodes were associated with a non-significant
trend to slower progression, however. Thus, in a broad sense,
immunologic factors are major determinants of the appearance
of chronic rejection, perhaps even initiators, but alter the
chronic rejection process gains ascendancy, these factors have
lesser effects on the rate of decline in function.
Other processes can simulate or coincide with chronic rejec-
tion. Recurrent disease, while confined in its most frequent
forms to a relatively small number of diagnostic categories, can
have a course clinically indistinguishable from that of chronic
rejection [201. Cyclosporine toxicity can mimic chronic rejec-
tion not only clinically but histologically, and the clean disen-
tanglement of these two entities is currently problematic if not
often impossible [21]. Renal artery stenosis can lead to wors-
ening hypertension and also can be marked by progressive renal
insufficiency. Such lesions usually can be excluded by nonin-
vasive means, especially Doppler ultrasonography [22]. Uri-
nary obstruction, yet rarer as a chronic complication compro-
mising function, also can be detected by noninvasive imaging
procedures. Finally, de-novo renal diseases, that is, the glomer-
ulonephritides or metabolic injuries such as myeloma kidney,
are not precluded in the patient with a long-standing renal graft.
Thus, the final confirmation of chronic rejection as the cause of
progressive erosion of function in the long-standing renal graft
often requires biopsy.
The histopathologic changes associated with chronic allograft
injury and subsumed under the general heading of chronic
rejection can be divided into three anatomic categories: large
vessels, glomeruli, and the tubulo-interstitium (Fig. 2) [23—25].
Chronic vascular changes are characterized by thickening of the
intimal layer, with progressive luminal occlusion being the final
result. This process is usually most apparent in arcuate and
interlobular arteries, but similar changes can occur in the main
renal artery itself, and analogous changes such as hyalinization
can extend into the microvasculature of afferent and efferent
arterioles. The increase in intimal thickness of the arteries
results from myointimal and smooth muscle cell proliferation
along with an increase in various components of normal ground
substance including collagen. In addition, the internal elastic
lamina of the larger vessels can be disrupted. Within the
glomerulus, ischemia and glomerular collapse are thought to be
the major downstream pathologic consequences of vascular
narrowing, but modest increases in mesangial matrix usually
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Fig. 2. A. Low-power photomicrograph of a
transplanted kidney with chronic rejection
shows large areas of fibrosis and tubular
atrophy. B. Arcuate artery is occluded by
intimal hyperplasia.
occur concomitantly with scattered subendothelial deposits.
The vascular walls and glomerulus contain 1gM deposits. The
juxtaglomerular apparatus frequently hypertrophies in the set-
ting of chronic vascular rejection; this development probably
represents a physiologic response to the decreased perfusion
due to the narrowing of the upstream arteries.
Glomerular changes more distinctive than those of simple
ischemia and collapse have been termed transplant glomerul-
opathy [24, 25]. This lesion, less commonly observed than the
vascular occlusive changes I just discussed, can occur any time
after transplantation. The process appears to move through an
early period dominated by endothelial swelling, followed by an
increase in subendothelial amorphous deposits leading to sep-
aration of the overlying endothelium from the glomerular base-
ment membrane. Often the mesangial matrix is also expanded in
this setting, and the peripheral capillary develops a double
contour notable on light microscopic examination. This change
is due mainly to the subendothelial deposits but also is pro-
duced by the occasional interposition of mesangial cells. Trans-
plant glomerulopathy is usually accompanied by proteinuria,
occasionally in the nephrotic range. Immunofluorescence find-
ings can be nonspecific but are marked by 1gM deposits in the
capillary wall and mesangium along with lesser amounts of C3.
The tubulointerstitial compartment demonstrates abundant in-
creases in interstitial ground substance with the appearance of
large-scale scarring. Mononuclear cell infiltrates consisting of
monocyte/macrophages and lymphocytes of both the helper and
cytotoxic varieties are also components of the tubulointerstitial
pathology [24—26]. The tubular epithelium becomes atrophic,
and its proportional contribution to this compartment recedes
with progression of the disease.
Even though available immunosuppressive therapies have
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Fig. 2. C. Glomerulus shows segmental
sclerotic changes (arrowhead) and the
adjacent juxtaglomerular cells are
hypertrophic (arrow). U. Glomerulus
demonstrating changes of chronic transplant
glomerulopathy with capillary walls showing
thickening and double contours (arrowhead).
(Courtesy of Dr. Barbara Burke, University of
Minnesota.)
been of no avail, and no clear scheme of immunologic processes
can be incriminated for chronic rejection, an immune compo-
nent to the process seems certain, as I noted earlier. However,
non-immune mechanisms potentially common in other progres-
sive renal diseases may add to or conspire with those deriving
from histoincompatibility. The greater rate at which cadaveric
grafts are lost, as contrasted with the rate at which living-
related-donor grafts are lost, supports a role for immune pro-
cesses; other clinical correlates (such as the number of acute
rejection episodes) also provide evidence for the role of immune
forces in chronic rejection. However, the specific immune
effectors are far from certain [1—5]. Both acute and chronic
injuries to transplanted kidneys are marked by the presence of
mononuclear cellular infiltrates [24—27]. While the degree of
cellular infiltration clearly is greater in acute rejection, the same
effector cells are present in both circumstances. That is, mono-
cyte/macrophages and T-cells are the predominant invading
cells, with a varying proportion of cytotoxic and helper T-cells.
Investigation of the cellular components of acute and chronic
injury has demonstrated that in the acute lesion, T-cells account
for the cytotoxicity, whereas in the chronic lesion, both T-cells
and non-T-cells appear to contribute to the cytotoxicity of the
cellular infiltrates in vivo. Also, antibodies specifically directed
against endothelial cells might be an important effector mecha-
nism in chronic vascular injury in renal allografts [281. The
presence of such antibodies directed to non-histocompatibility
antigens on the endothelial cell has been proposed as a mech-
anism of injury. The injury induced by this antibody is envi-
sioned to include thrombosis in the microvasculature with the
local production of both platelet-derived and locally produced
growth factors and cytokines [28]. However, even the clear
presence of such antibodies in clinical material and experimen-
tal models does not necessarily prove a causal role for them.
Finally, non-immune mechanisms initiated through the re-
sponse to acute rejection might determine the degree of chronic
injury. Indeed, acute rejection episodes can be a powerful
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predictor of late function [18, 29, 30]. Such acute rejection
episodes might function in part to reduce the nephron number,
function, or both. In this scenario, acute rejection episodes
would determine the amount of functioning renal tissue and
hence the degree of alterations (adaptive and maladaptive) that
ensue in less damaged nephrons. An important effect of simple
nephron destruction would not exclude persistent immune
attack as an additional destructive force, perhaps through
immune mechanisms distinct from those of acute rejection.
Indeed, the presence of similar chronic vascular injury in other
transplanted organs suggests that some common damaging
mechanisms are related to the alloresponse per se and are not
solely dependent on nephronal function and adaptation [1—4].
Ischemia of the cadaveric graft also might constitute an
additional mechanism whereby such kidneys are rendered more
susceptible to long-term damage. Ischemic injury, usually fall-
ing under the heading of delayed graft function, has been
associated with decreased survival of the allograft even long
after transplantation [31—33]. Significant associations between
delayed graft function and subsequent graft performance have
been noted as long as 6 years following transplantation.
Whereas not all reports describe such a clear relationship, the
general trend is that delayed graft function adversely influences
long-term survival [34]. Whether specific structural lesions
underlie the late erosion of function that occurs on an ischemic
background is uncertain. This effect of early ischemia on late
function has been reproduced in experimental animals. Using a
rat renal allograft model, Yilmaz and colleagues showed that 60
minutes of graft ischemia led to greater vascular and glomerular
injury 12 weeks following transplantation than did 30 minutes of
ischemia [35]. At that point, serum creatinine values were also
higher in the group with the more ischemic kidneys at the time
of transplantation despite having fallen earlier to baseline. The
studies of allografted kidneys also were paralleled by studies
with syngeneic grafts in which 60 minutes of ischemia had no
detectable adverse effect on serum creatinine concentration or
histologic changes after 12 weeks. These studies were per-
formed with a normally functioning native kidney contralateral
to the variably ischemic graft for the first week after grafting, at
which time it was removed, leaving only the graft for the
duration of the study. Although suggestive, these studies thus
are confounded to some degree by the presence of the native
kidney, given the normal kidney's ability to attenuate recovery
from ischemia in a contralateral kidney [36, 37]. Indeed, clinical
studies also have suggested that the presence of native kidneys
may lessen the survival of grafts [311. The function of most such
native kidneys is low, however, and the mechanisms responsi-
ble for this clinical observation might not be the same as for the
experimental one. Nevertheless, the apparently greater impact
of ischemia on an allograft compared with the syngeneic graft
argues for some interaction between histoincompatibility and
ischemia.
Several hypothetical mechanisms can be suggested to explain
this interaction. First, the initial ischemic injury might reduce
the number of functioning nephrons. But even in animal models
of ischemia alone, data enumerating the functioning nephron
population after recovery from ischemic injury are not avail-
able. The possibility of a simple sudden loss of some fraction of
nephrons therefore remains intriguing but speculative. An ad-
ditional possibility is that neoantigens expressed by the renal
epithelium following ischemic injury might abet immunologi-
cally mediated injury. For example, 24 hours after acute renal
ischemia in mice, class-I and class-Il MHC antigen expression
is increased in renal tubular epithelial cells [38]. The increased
class-Il antigen level is especially intriguing because renal
tubular epithelial cells do not express this class of antigen in the
basal state. The possibility has been raised that the expression
of class-Il antigen—which normally functions in the antigen-
presenting machinery of dendritic cells, B-cells, thymic cells,
and macrophages—promotes a local autoimmune injury and
thereby propagates ongoing renal injury in conditions such as
lupus nephritis [39]. Recent evidence suggests, however, that
the transgenic expression of class-Il antigens in the renal
epithelium is not sufficient in itself to initiate injury, perhaps
because co-stimulatory molecules are absent [40]. Ischemia-
induced class-LI antigen expression might at least contribute to
the long-range damage to an initially non-functioning kidney.
Prevention or moderation of ischemic injury might in part
underlie the beneficial results described for early administration
of calcium antagonists to cadaveric renal transplant recipients,
as the vasodilatory or even direct cellular effects of these drugs
might lessen ischemic damage [41].
Cyclosporine directly reduces renal function by both vaso-
constrictive and vasoocclusive actions [21]. It might contribute
indirectly to chronic allograft injury through its hypertensive
effects as well as by reducing functioning numbers of nephrons
through ischemia with other adaptive/maladaptive mechanisms
then called into play. The histologic changes associated with
chronic cyclosporine toxicity are nonspecific [42]. The intersti-
tial fibrosis may be more band-like than in chronic rejection, but
the modest cellular infiltrate, the occasional glomerular sclero-
sis, the tubular atrophy, and the arterial hyaline changes are
common to chronic rejection even without cyclosporine.
Whether rates of graft loss in the long term are related to
cyclosporine is less certain, although the problem of chronic
graft loss seems not to have improved with the introduction of
cyclosponne as routine treatment for transplant recipients [43].
A report of a greater prevalence of chronic rejection in patients
taking lower doses of cyclosporine possibly reflects deficient
immunosuppression but also might result from intentional dose
reductions in patients with poor function [18]. But the possibil-
ity exists that the efficacy of this agent in reducing the incidence
of acute rejection has been to some extent counterbalanced by
its own nephrotoxicity. If so, the net result could therefore yield
the observed constant long-term graft loss despite increases in
early graft survival.
Cyclosporine, acute rejection, and ischemia might each re-
duce nephron mass following transplantation, but it has been
proposed that the actual initial number of transplanted neph-
rons, or a surrogate marker, the mass of the graft, also
determines its long-term function [44]. In essence, this view
holds that a mismatch between the metabolic demand of the
host and renal excretory function (normally served by the
native kidneys) would, if the host's demands exceed the size of
the grafted kidney, lead to adaptations in that kidney, and that
these adaptations are deleterious, as shown in other renal
injuries. A number of observations have been marshalled in
support of this view. For example, kidneys from either very
young or old donors tend to do less well over a 3-year period
[44]. These results can be construed as a reflection of a normal,
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aging-induced reduction of mass in the latter case, and in the
former simply a smaller kidney in an adult host. But nephron
number is believed to be at its adult level in human neonates, so
another feature of an infant donor's kidney likely predisposes to
injury. The less favorable response might simply reflect techni-
cal difficulties with surgical engraftment of small kidneys, but it
also might represent a more subtle and disadvantageous effect
of a rapid increase in growth in these initially small kidneys
placed under the metabolic demand of the adult recipient [45].
That is, some yet unspecified feature of accelerated growth in
the setting of immunologic incompatibility might be a condition-
ing factor distinct from the absolute number of nephrons
transplanted. Larger graft recipients appear to be at greater risk
for poor graft function, perhaps because the kidneys they
receive are too small for their size or metabolism [44]. Again,
however, seemingly trivial issues—including difficulties of im-
munosuppressive drug dosing in frankly obese patients—might
at least partially account for this observation. The somewhat
poorer graft survival in male than female recipients has also
been raised as a potential example of the liability of greater
body size and the metabolic demand it entails. Despite the
possibility that technical difficulties might account for portions
of these observations, and the obvious uncertainty as to the
exact physiologic forces being placed at odds (for the graft:
kidney size, maturity, nephron number, etc., versus for the
host: body size, nitrogen excretion, acid generation, etc.), the
argument that more appropriate physiologic matching might
improve outcome is an appealing one.
The loss of functioning nephrons inspires numerous adapta-
tions in those surviving. These adaptations include structural
growth, hemodynamic adjustments, augmentation of salt and
water transport, heightened ammoniagenesis, and others [46].
Generally these adaptations have been viewed as homeostatic
responses to the increased work of surviving nephrons, with the
resultant maintenance of more nearly basal, normal metabolic
parameters. But over the last decade, several of these adapta-
tions have been singled out as potentially deleterious, in the
long run predisposing such adapted nephrons to further injury
[46—48]. Many, if not all, chronic renal diseases have certain
"final common pathways" of progression that proceed not only
through the stresses imposed by such adaptations on surviving
nephrons but also because of the accumulation of potentially
toxic products consequent to loss of renal function. Not only
does the transplanted kidney initially contribute at best only
one-half of normal renal function, but under the combined
effects of acute rejection, ischemia, cyclosporine toxicity, and
the vagaries of nephron number provided by the graft, substan-
tially less than one-half can actually be accorded the recipient.
The most intensively studied of these adaptations are the
hemodynamic ones [49]. With the loss of renal mass, single-
nephron GFR increases markedly in the remaining nephrons as
they simultaneously undergo hypertrophy and hyperplasia.
Elevations in glomerular capillary pressure and plasma flow
account for the increases in residual nephron filtration. The
augmentation of glomerular capillary pressure and flow result
from striking vasodilation in both the pre- and, to a lesser
extent, the post-glomerular microcirculation. In the case of the
animal models of reduction in renal mass, the remnant kidney
model, severe pathologic alterations appear in initially normal
residual glomeruli during this process of adaptation. These
changes eventuate in glomerular sclerosis and are attended by
proteinuria consequent to major alterations in the permselective
properties of the residual glomeruli. That glomerular hyperper-
fusion and capillary hypertension cause the progressive damage
to residual glomeruli is supported by the observations that
maneuvers such as dietary protein restriction and certain types
of antihypertensive therapy, both of which attenuate glomerular
capillary pressure, also lessen the subsequent proteinuria and
glomerular structural injury [49, 50]. The association of glomer-
ular hypertension with injury, and its diminution with mitiga-
tions of injury, has been extended to a variety of experimental
diseases [49]. Furthermore, therapeutic maneuvers consistent
with this scheme, especially antihypertensive treatment, have
been clinically successful in ameliorating chronic renal irury.
Paul and coworkers have reported that glomerular capillary
pressure is elevated in a rat model of chronic rejection [51]; this
finding was confirmed in our laboratory [52]. A preliminary
report also finds that reduction of capillary pressure with
antihypertensive treatment diminishes injury in that model [53].
Arterial hypertension is associated with worse histologic dam-
age in clinical chronic rejection and correlates with declining
function, and these findings argue circumstantially for a dam-
aging effect of heightened vascular and even capillary pressures
[10, 15]. Despite the suggestive evidence, direct clinical proof of
the long-term benefit of antihypertensive therapy on renal
transplants is lacking. Although a retrospective analysis failed
to detect a beneficial effect of antihypertensive treatment on
graft survival, the retrospective nature of the data and the
possibility that specific agents could be especially effective
should lead to caution in interpretation of this observation [16,
49]. In addition, a preliminary report of a prospective study
noted no added benefit when a converting enzyme inhibitor was
added to the therapeutic regimen of transplant recipients who
had declining function, hypertension, or both. I should note,
however, that the study only contained a relatively small
number of patients (13 treated with drug and 16 with placebo)
[54].
Converting-enzyme inhibitors have shown especially benefi-
cial effects on the course of several clinical and experimental
renal diseases. Interruption of the renin-angiotensin system has
yielded greater protective actions on the kidney than have other
antihypertensive strategies [55, 56]. Furthermore, the renin-
angiotensin system has been incriminated in generating hyper-
tension post transplantation [14]. Among the mechanisms pro-
posed for this latter effect have been the increased number of
kidneys as additional sites of renin production (when native
kidneys are left in place); the effects of glucocorticoids, which
increase angiotensinogen levels; and the effects of interstitial
scarring and vascular occlusion, which provoke renin produc-
tion presumably due to local intrarenal ischemia [14, 15]. With
respect to the latter possibility, hypertrophy of the juxtaglomer-
ular apparatus is a common anatomic feature of chronic rejec-
tion and likely bespeaks focal hyper-secretion of renin [24, 25],
Higher plasma renin activity also has been reported in patients
with late worsening of graft function [57]. In the remnant kidney
model, glucocorticoids heighten glomerular capillary pressure
and worsen injury [58]. Perhaps these effects are related to their
stimulation of angiotensinogen production as they were abro-
gated by converting enzyme inhibition [58]. Of related interest,
vascular injury sustained by experimental aortic allografts was
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lessened by converting-enzyme inhibition [59], and a prelimi-
nary report notes an attenuation of renal injury with such
therapy in rats with renal allografts [53]. A short-term clinical
study also has demonstrated a reduction in proteinuria with
converting-enzyme inhibition in hypertensive patients who
have long-standing grafts [60]. Taken together, these observa-
tions suggest a role for the renin-angiotensin system in chronic
rejection, although converting-enzyme inhibition had no clear
effect on renal functional decline in a small group of renal
transplant patients [54]. However, converting-enzyme inhibi-
tors as well as calcium-channel blockers also appear to be
effective in controlling arterial pressure in these patients [61]. A
note of caution is due with regard to converting-enzyme inhi-
bition, as patients who harbor significant degrees of renal
vascular narrowing within their single functioning graft can
develop rapid and severe renal failure [621. Thus, especially
careful monitoring of serum creatinine is necessary in the first
week or two of therapy with these drugs in renal transplant
patients.
Prostaglandins have been implicated in several aspects of
graft injury, including the immune response of acute rejection,
as components of the platelet interaction with injured endothe-
hum, and as mediators of cyclosporine toxicity [1, 21. Various
strategies have been employed in the hope of favorably altering
the balance of deleterious and beneficial prostanoids. Whereas
some encouraging results have been obtained in chronic rejec-
tion or models thereof with cyclooxygenase inhibitors, throm-
boxane antagonists or fish oils, and prostacyclin analogues,
definitive proof of long-term benefits and definition of the best
of these strategies is not available [1, 2, 63].
Growth occurs in residual nephrons following the loss of
renal mass [46]. Furthermore, a number of renal diseases
display renal or glomerular growth as forerunners of overt
disease. Examples include diabetes, sickle cell disease, cya-
notic heart disease, and oligomeganephronia [64, 65]. Such
associations exist also in experimental diseases, with large
glomeruli preceding sclerosis and more advanced glomerular
injury [64, 65]. For example, we demonstrated that with alter-
ations in dietary sodium intake in the remnant kidney model,
variations in glomerular volume could be induced with rela-
tively constant glomerular capillary pressures [661. Rats with
larger glomerular volumes developed greater injury; this finding
is consistent with that of Dworkin and coworkers [67]. These
observations have led to the hypothesis that growth represents
another adverse adaptation of the remnant nephron. A number
of potential mechanisms have been proposed to account for the
effect of glomerular enlargement on subsequent injury. First,
increases in glomerular size—even with a constant transcapil-
lary pressure.—would be predicted to increase wall tension by
the LaPlace relationship, an effect that can mechanically dis-
rupt the glomerulus [66]. Also, the enlargement of glomeruhi and
the preglomerular vasculature may subserve the hyperfiltration
and damaging capillary hypertension due to the lower vascular
resistance expected with greater vascular caliber. In addition
Miller et al showed that as the glomerulus enlarges, the visceral
epithelial covering can prove insufficient and result in areas of
denuded basement membrane [68]. The normal permselective
properties are lost, and proteinuria results from the denuded
sites. Finally, the possibility exists that increases in the size of
the mesangial compartment interfere with its clearing mecha-
nisms and allow accumulation of macromolecules or otherwise
disturb its metabolism. The role of glomerular hypertrophy as a
specific mechanism determining chronic injury to the trans-
planted kidney has yet to be proven, however. Using biopsy
material, Kasiske and colleagues demonstrated that enlarge-
ment did occur in the glomeruhi of transplanted kidneys, but the
enlargement in individual patients did not predict a subsequent
decline in renal function [15]. If hypertrophy depended impor-
tantly for its adverse effects on an interaction with such
functional parameters as glomerular pressure, then it might be
difficult to discern any effect based solely on structural (histo-
logic) data.
Adaptations in tubular function occur pari passu with those of
glomerular structure and hemodynamics. Sodium transport for
residual nephrons increases in simplified models such as the
remnant kidney [46]. This increase in sodium transport obli-
gates an increase in energy expenditure and oxygen consump-
tion by these nephrons. Indeed, we have shown that the
increase in oxygen consumption is even greater than that
predicted from increases in sodium reabsorption [69]. The
reason for this increase is not entirely clear, but several
investigators have suggested that the heightened metabolism
generates injurious consequences. Specifically, the generation
of oxygen free radicals has been proposed as an injurious
consequence to increased oxygen consumption [69, 70]. Evi-
dence of increased oxidant stress has been noted in the remnant
kidney model with elevations of lipid peroxide products and
alterations in redox ratio in favor of an oxidizing environment
[69]. Supplementation of anti-oxidant compounds diminishes
injury in this model [71]. Possibly, similar mechanisms might
occur as nephron numbers fall in other circumstances, including
those operating in the chronically rejecting kidney. But whether
anti-oxidant supplementation would favorably influence this
process is not known.
With an experimental reduction of renal mass, and in the
clinical setting as well, ammoniagenesis increases in residual
nephrons [48, 50]. Whereas this response assists in the mainte-
nance of acid balance, adverse renal consequences also can
follow from heightened ammoniagenesis. Studies of chronic
injury in animal models have demonstrated that reductions in
ammoniagenesis by bicarbonate supplementation lessen
chronic tubulointerstitial disease [72]. The mechanism believed
responsible for this inflammatory effect of ammonia is the
interaction of ammonia with the C3 component of complement.
This reaction leads to an amidated C3 with the capacity to
engage white cell receptors, trigger their toxic action, and
generate the cytolytic terminal complement cascade. As with
oxidant injury, no clinical data exist to assess the role of this
mechanism in chronic transplant rejection, although the finding
of complement deposition in the tubular interstitial compart-
ments in many chronic renal injuries (irrespective of the initi-
ating process) is consistent with this possibility [72]. Also, the
ability of glucocorticoids to increase ammoniagenesis might
provide an additional driving force for this pathway in the
transplanted kidney [73].
Dietary protein restriction generally has been effective in
slowing the course of experimental and clinical renal disease
[47, 74], although the recent U.S. MDRD Study was not able to
demonstrate uniform clinical efficacy of modest protein restric-
tion [75]. The mechanisms of this effect are likely multiple and
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probably include reduction of glomerular capillary pressure,
diminution of renin synthesis, decreased ammoniagenesis, and
other metabolic actions. In the case of chronic rejection,
several studies have demonstrated either uncontrolled or short-
term benefits of protein restriction [17, 76]. For example,
Feehally et al reported a lessening of the decline in the inverse
of serum creatinine over time after protein restriction in a small
group of long-term transplant patients, but no control subjects
were studied [76]. Salahudeen and coworkers demonstrated a
reduction in proteinuria with short-term protein restriction in
subjects with biopsy-proven chronic rejection [17]; this result
suggests a beneficial renal response given the general associa-
tion of greater proteinuna with worse outcomes (Fig. 3) [11, 13,
15, 17]. However, the level of protein intake at .55 gfkg body
weight might have been insufficient; serum protein levels de-
clined even though this degree of protein restriction has been
well tolerated in normal subjects and in those with renal
insufficiency without transplants [17]. Perhaps even the low
dose of prednisone required by these patients (averaging 14
mg/day [17]) necessitates a more generous protein allowance. In
any case, protein restriction might be beneficial in this setting.
A firm demonstration of long-term benefits is not available, and
the exact level of restriction consistent with safety is not
known.
The specific molecular signals for interstitial scarring, vascu-
lar occlusion, glomerular sclerosis, and the other chronic
changes of late renal allograft pathology have begun to be
explored. Platelet-derived growth factor (PDGF) and trans-
forming growth factor f.3 (TGF) have been incriminated fre-
quently in non-transplant progressive vascular injury and gb-
merular sclerosis [77—79]. Specifically, these factors appear in
the glomeruli of animals in a variety of experimental renal
injuries and might function as local factors to increase mesan-
gial cell proliferation and mesangial matrix production, thereby
mediating the scierosing process. Their source may include
circulating platelets and other blood cells as well as resident
glomerular cells, including gbomerular macrophages and mesan-
gial cells. However, a firmer causal assignment for PDGF or
TGF as mediators of chronic glomerular injury awaits the
availability of experimental means to block or delete them
selectively. In the case of TGFI3, brief blockade with specific
antibodies or with decorin (a proteoglycan that binds TGF/3)
favorably alters the course of short-term experimental diseases
[78]. In experimental chronic allograft rejection, the PDGF-p
receptor in rat heart and kidney grafts and the mRNA for PDGF
increase; these findings suggest a role for PDGF in experimental
chronic allograft injury [80]. In addition, growth-inhibiting
properties of heparin and the somatostatin analogue atriopeptin
might underlie the beneficial effects shown by these agents in
experimental vascular injury including, in the case of atriopep-
tin, vascular injury in heart albografts [2]. Whether heparin or
atriopeptin works against specific growth-regulating factors
and, most importantly, whether they are clinically effective is
not known. Hancock and colleagues have recently reported
increased tissue staining for several cytokines including IL- 1,
IL-6, and TNFa in long-term rat renal allografts [81]. These
authors speculate that these factors, especially IL-6, might
contribute to dysfunction by several pathways including prolif-
eration of matrix production by mesangial cells. In addition, the
up-regulation of the adhesion molecule ICAM- I in these same
allografts possibly promotes the lodging of host leukocytes in
the graft [14].
The exact stimuli for the synthesis and release of PDGF,
TGFp, or other local factors are unclear in most disease
models, including allograft injury. Immune activation or recruit-
ment of inflammatory cells, as well as local vascular trauma
(perhaps with platelet or monocyte release), probably consti-
tute such stimuli [77, 78]. In addition, local activation of the
renin-angiotensin system with production of angiotensin II
likely incites such factors both by way of its injurious hemody-
namic actions as well as via direct cellular effects. Both PDGF
and TGFI3 production have been evoked in various cells by
angiotensin II, and blockade of the renin-angiotensin system
can reduce the message for at least TGF3 in non-transplant
models of chronic renal disease [82—85]. The renin-angiotensin
system, in view of its potential activation in chronic rejection,
thus might be one factor initiating the cascade of local genera-
tive, shaping, and scarring factors.
In summary, chronic rejection is a quantitatively important
cause of chronic progressive renal disease. Both immune and
non-immune mechanisms, the latter common to other chronic
renal diseases, likely participate in the injury (Fig. 4). However,
the pathogenesis of chronic rejection is only beginning to yield
to investigation, and no specific therapy is yet available. Sys-
tematic clinical investigation, study of animal models, and
techniques for selective manipulation of putative effectors are
required to expand our knowledge and, in consequence, im-
prove the outcome of transplant recipients.
QuestIons and answers
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): In the
ablation model of chronic renal failure, "activated" phenotype
with expression of new antigen, that is, a-smooth muscle actin,
has been described in the mesangial cell converting it to a
A
80
70
60
50
40
30
20
10
I
12
2
.2 . 9
___
I:
High Low
Fig. 3. Fractional clearances of albumin (panel A) and IgG (B) in
patients with biopsy-proven chronic rejection after 11 days on a high- or
low-protein diet. Permselectivity was better on the low-protein diet
(* P < .05). (From Ref. 17.)
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Common pathways
of progression
"myofibroblast" [86], This transformation is reminiscent of the
myointimal proliferation you referred to in the cardiac trans-
plant model in the rat. I was wondering whether such "activat-
ed" phenotypes as well as increased expression of growth
factors have been identified in experimental models of cardiac
or renal allografts.
DR. HOSTETTER: To my knowledge, no one has actually done
the staining that Floege and colleagues did in the ablation model
in transplantation or a model thereof. One would predict that
there would be such a transformation of mesangial cells,
because these authors argue that an increase in capillary
pressure is a first step that is somehow translated through a
transduction system by the mesangiat cells, making them more
like smooth muscle cells. If that is a necessary step—high
pressures being the phenotypic switch—you would predict that
transformation of mesangial cells into myofibroblasts would
occur also in transplants. Regarding local growth factors and
cytokines, a rapidly increasing number have been identified in
experimental and clinical chronic rejection. For example,
PDGF and the PDGF receptor /3 subunit are increased in clinical
and experimental chronic rejection, as are IL-6 and TNF-a [80,
81, 87]. Also, TGF/3 has been identified in clinical chronic rejec-
tion [87, 881. The precise roles of these and probably other local
factors undoubtedly will emerge in the future.
DR. MADIAS: Erythropoietin increases after renal transplan-
tation in humans and, as you know, several associations be-
tween this system and the renin-angiotensin system are now
recognized. Could you speculate on a potential role of erythro-
poletin in the hypertension and vascular injury of the renal
allograft recipient?
DR. HOSTETTER: I have been struck by the observations that
converting-enzyme inhibitors lower post-transplant erythropoi-
esis, so I'm intrigued by the possibility that angiotensin II
drives oxygen consumption by the proximal tubule with a
resultant lower cortical P02 and stimulation of erythropoietin
secretion by oxygen sensors. It's possible that the hyperten-
sion, particularly in the patients who have frank erythrocytosis,
is damaging to these kidneys.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I'm skeptical
about your explanation for poorer outcomes of the donor
kidney from individuals under the age of 3 years. What other
possible reasons, for instance, multiple or small blood vessels,
might make transplantation less successful than if the donor
were a 40-year-old?
My second question is broader. Rather than simply taking
individuals under age 3 and over age 60 and looking at the
outcome, couldn't you measure kidney weight in all donors and
correlate weight with outcome?
DR. HOSTETTER: I think the technical surgical issues are real
for the very small kidneys. Kidney weight appears to be a
reasonable correlate of nephron number, at least in adults [89],
and might hold an interesting correlation with graft outcome. As
for kidneys from older donors, these seem to do less well; a
preliminary report suggests that age-related nephrosclerosis
might be a determinant of this poorer outcome [90, 91].
DR. MADIAS: Other vascularized grafts suffer chronic vascu-
lar injury, notably the accelerated atherosclerosis seen in the
coronary arteries of cardiac transplant patients. Is this process
mechanistically similar to the vascular injury of chronic renal
transplant rejection?
DR. HOSTETrER: Chronic allograft injury is common to all
solid organs; vascular injury of a generally similar pattern is
also common. Additionally, more organ-specific features are
notable, such as the glomerular and tubulointerstitial diseases in
kidney, vanishing bile ducts in liver, and chronic bronchiolitis
obliterans in lungs. The working hypothesis seems to be that
functionally important chronic vascular injury, with a resultant
lschemia
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concentric coronary lesion in hearts and vascular narrowing in
kidneys, has a common mechanism involving endothelial in-
jury, perhaps by monocytes, followed by smooth-muscle pro-
liferation [1—3, 92]. A number of cytokines and growth factors
might be involved as well as other variables such as cytomeg-
alovirus infection, plasma lipids, and vascular pressure. Indeed,
I would speculate that these coronary and intrarenal vascular,
including glomerular, lesions are so conspicuous because of the
relatively high intravascular pressure sustained at these sites in
contrast with other vasculature such as the pulmonary circula-
tion.
DR. RICHARD LAFAYETFE (Division of Nephrology, New
England Medical Center): Now that a model of chronic rejec-
tion is available to test conditions following allogeneic versus
isogeneic transplantation, one should be able to sort out influ-
ences of immune activity or low nephron number. For instance,
one might transplant an allogeneic graft into an animal that has
a full complement of nephrons and see whether chronic rejec-
tion occurs and progresses. On the other hand, if it is techni-
cally possible, one might take an allogeneic graft undergoing
chronic rejection and retransplant it into an isogeneic host to
see whether rejection continues. Has any of this been done or
considered?
DR. HOSTETrER: To my knowledge, the latter experiment has
not been, but the former has been reported. A recent abstract
by Mackenzie and coworkers noted a reduction in chronic renal
allograft injury when a native kidney was left in place [93].
DR. LAFAYETrE: I have a second, unrelated question about
cyclosporine use in chronic rejection. Perhaps chronic rejection
can be controlled at higher cyclosporine levels because the
afferent arteriolar constriction prevents glomerular hyperten-
sion. Has anyone pursued that possibility or suggested that
hypothesis to explain why higher cyclosporine levels are asso-
ciated with fewer episodes of chronic rejection?
DR. HOSTErFER: No, but it's an interesting possibility. I
don't know of any animal study that investigated that exact
point, but it would be consistent with what we do know from
cyclosporine's physiologic effects in other experimental situa-
tions.
DR. MADIAS: I believe that low-salt diet has been shown in
some studies to improve glomerular morphology and reduce
glomerular volume in the ablation model of chronic renal failure
in the rat [66, 67]. What do these observations say about the
pathogenetic significance of an activated renin-angiotensin sys-
tem for progression in this model?
DR. HOSTETTER: That's been done by a couple of people.
Barbara Daniels in our group has shown that, and Lance
Dworkin also has similar results, but both studies were in
models other than transplantation. The candidate effectors for
this phenomenon would seem to be atrial natnuretic peptide or
perhaps nitric oxide [94].
DR. HARRINOTON: You alluded to the disappointing results of
the U.S. MDRD study, that is, that little or no difference could
be found in the low-protein group versus the normal-protein
group [75]. How will the results of that study affect the
management of your patients who have chronic transplant
rejection? Second, what is the role of hyperlipidemia in chronic
vascular injury?
DR. HOSTETTER: The results of the MDRD study seem mixed
to me, Dietary protein restriction might be useful in combating
chronic rejection, but it has not been sufficiently tested to
recommend it generally now. If employed, it probably should
be reserved for patients with demonstrated progression of
chronic rejection and proteinuria and in conjunction with blood
pressure control. In addition, the level of protein intake should
probably be no lower than 0.7 g/kg/day with adequate calories
and monitoring of nutritional status, as these patients might
have a higher minimal requirement for protein than do non-
transplant patients [17]. Hyperlipidemia has inconsistent effects
in experimental models and an uncertain role in graft injury
clinically [1—3]. In view of the high prevalence of extrarenal
cardiovascular disease in the patients, however, attempts at
lipid control seem reasonable.
DR. MADIAS: Have you observed changes in plasma renin
activity in response to changes in protein intake in your
transplant patients?
Da. HOSTETrER: Yes, the transplant patients, like normal
people and people with native kidney disease, have higher
plasma renin activity on high-protein diets [17, 55].
DR. HARALD MACKENZIE (Renal Division, Brigham and
Women's Hospital, Boston): I was involved in the studies, so I
can confirm your answer to the earlier question about trans-
planting a single kidney in the Fisher-Lewis rat model into a
bilaterally nephrectomized recipient compared with transplant-
ing a kidney into a recipient having one native kidney preserved
[93]. We carried out these studies in Dr. Brenner's laboratory in
collaboration with Dr. Tilney's group and found that the pres-
ence of additional renal mass in the form of the native kidney
protects the allograft from developing proteinuria and chronic
structural injury. My question relates to the case presented.
Since the two transplanted pediatric kidneys will undergo, in
the short term, considerable structural and functional hypertro-
phy, which in the longer term may prove detrimental, would
you consider giving an ACE inhibitor in this or similar select
cases, even before results of clinical trials are available?
DR. HOSTETrER: Yes, I would and do. However, more than
usual caution should be applied, because GFR can drop precip-
itously if significant renal vascular disease is present [62]. Thus,
the serum creatinine level should be followed closely in the first
week or two after using such a drug in this setting.
DR. JULIE NEURINGER (Division of Nephrology, New En-
gland Medical Center): In your studies in transplant patients,
you showed that a correlation between blood pressure and
progression rate existed even within the normal range of
diastolic blood pressure. Given that, how tightly are you trying
to control your transplant patients' blood pressures?
DR. HOSTETTER: We try to lower the mean arterial blood
pressure below 95, so that it is about 120/80 mm Hg. In the
analysis that Francesca Modena did of blood pressure and rates
of progression [10], diastolic pressure was the strong correlate,
and the rate of progression was very low at diastolic pressures
below 90 mm Hg.
DR. HARRINGTON: You stated that ammonia and complement
might be related in some way to chronic rejection. Has anyone
given experimental animals enough bicarbonate to offset endo-
genous acid production, thus keeping their plasma bicarbonate
normal, to see whether this approach really makes a difference?
Second, does endothelin or nitric oxide play a role in chronic
rejection?
Da. HOSTETrER: No one has tested alkali supplementation in
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chronic rejection, although dietary protein restriction does
entail a reduction in acid load among its other effects. Endo-
thelin has been quite plausibly proposed as a mediator of
chronic renal injury, for example, in the remnant kidney model
[94], but a preliminary report failed to note differences in its
plasma level in patients with chronic rejection [95]. Investiga-
tion of its renal levels is in order. I am not aware of studies of
nitric oxide in chronic rejection per Se, but the endothelial focus
of the injury suggests that that system also might be perturbed.
DR. HARRINGTON: Does acute dialysis in the immediate
post-transplant period, with its potential for complement and
cytokine activation, have any effect on late injury?
DR. HOSTETTER: It might but to my knowledge has not been
studied. The experimental data supporting such a general
possibility [96] and the clinical finding that delayed graft func-
tion has longer consequences [31—34] would be in accord with
this idea.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I agree that this is an important patient
population in which to study treatments to retard the progres-
sion of renal disease. Are you aware of clinical trials underway
in this group of patients?
DR. HOSTETTER: I am not aware of large trials directed at
these patients. Probably there are other relatively small and/or
short-term trials such as ours with protein restriction [17] or
that of Riggio and colleagues with converting-enzyme inhibition
[54]. These sorts of small studies, which will always leave some
doubts (as do even the large trials), should be useful in focusing
issues.
DR. HARRINGTON: Could you define your ideal study?
DR. HOSTETTER: Major problems in proposing such an ideal
trial are the relative lack of not only basic experimentally
derived data but also the paucity of systematic clinical risk
factors and natural history data. Thus, this sort of work along
with the small pilot-type trials, to which I just alluded, should
be encouraged. At present, a single, large-scale multicenter trial
would be premature if it sought to test an intervention. The
money and effort would be better spent on more of these
smaller-scale investigations.
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